薄芝糖肽与胸腺五肽分别联合重组人干扰素α2b治疗HBeAg阳性的慢性乙型肝炎的临床观察

发布时间：2018-06-15 02:07

本文选题：慢性乙型肝炎 + 重组人干扰素αb　；参考：《中国药房》2017年08期

【摘要】：目的:观察薄芝糖肽和胸腺五肽分别联合重组人干扰素α2b治疗慢性乙型肝炎的疗效及安全性。方法:选择2014年1月-2015年1月我院90例慢性乙型肝炎患者,随机分为A、B、C组,各30例。A组患者给予注射用重组人干扰素α2b(假单胞菌)500万IU皮下注射,qod;B组患者在A组基础上加用薄芝糖肽注射液4 m L加入5%葡萄糖注射液250 m L中,ivgtt,qd;C组患者在A组基础上加用注射用胸腺五肽2 mg加入5%葡萄糖注射液250 m L中,ivgtt,qd。3组患者均治疗24周。比较3组患者治疗4、8、12、24周丙氨酸转氨酶(ALT)复常率、HBeAg阴转率、HBeAg/抗HBeAg血清转换率(以下简称"HBeAg转换率")、HBV-DNA阴转率、乙肝表面抗原(HBsAg)和HBV-DNA下降量,治疗24周时的HBsAg阴转率,并记录不良反应的发生情况。结果:治疗4、8、12周,3组患者ALT复常率、HBeAg阴转率、HBeAg转换率、HBsAg下降量比较,差异均无统计学意义(P0.05)。治疗4周,B组和C组患者HBV-DNA转阴率显著高于A组,C组患者HBV-DNA下降量显著大于A组和B组,差异有统计学意义(P0.05)。治疗8、12周,B组和C组患者HBV-DNA阴转率和HBV-DNA下降量显著高于A组,差异有统计学意义(P0.05),但B组与C组间比较,差异无统计学意义(P0.05)。治疗24周,3组患者ALT复常率、HBeAg转换率、HBsAg下降量及HBsAg阴转率比较,差异均无统计学意义(P0.05);B组和C组患者HBeAg阴转率、HBV-DNA阴转率和HBV-DNA下降量显著高于A组,差异有统计学意义(P0.05),但B组与C组间比较,差异无统计学意义(P0.05)。3组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:薄芝糖肽和胸腺五肽分别联合重组人干扰素α2b对慢性乙型肝炎具有较好的抑制病毒增殖作用,且在ALT复常率、HBeAg转换率、HBsAg下降量及HBsAg阴转率方面效果相当。
[Abstract]:Aim: to observe the efficacy and safety of Ganoderma lucidum glycopeptide and thymus pentapeptide combined with recombinant human interferon 伪 2b in the treatment of chronic hepatitis B. Methods: from January 2014 to January 2015, 90 patients with chronic hepatitis B in our hospital were randomly divided into two groups. 30 patients in group A were treated with recombinant human interferon 伪 2b (Pseudomonas pseudomonas) 5 million IU subcutaneously injected subcutaneously in group B, on the basis of group A, the patients in group B were treated with 4 mL of Ganoderma lucidum injection and 250ml of 5% glucose injection. The patients in group A were treated for 24 weeks with the addition of 2 mg thymus pentapeptide for injection into 250 mL of 5% glucose injection. The HBeAg / anti-HBeAg seroconversion rate (HBeAg / anti-HBeAg seroconversion rate), HBV-DNA negative conversion rate, HBV-DNA decrease rate and HBsAg negative conversion rate at 24 weeks after treatment were compared among the three groups. Adverse reactions were recorded. Results: there was no significant difference in alt normalization rate, HBeAg negative conversion rate and HBeAg conversion rate and the decrease of HBsAg in the 3 groups after 12 weeks of treatment (P 0.05). The negative rate of HBV-DNA in group B and group C was significantly higher than that in group A and C at 4 weeks after treatment, and the decrease of HBV-DNA in group A was significantly higher than that in group A and group B. the difference was statistically significant (P 0.05). At 812 weeks, the negative rate of HBV-DNA and the decrease of HBV-DNA in group B and C were significantly higher than those in group A, and the difference was statistically significant (P 0.05), but there was no significant difference between group B and group C (P 0.05). After 24 weeks of treatment, there was no significant difference in alt normalization rate, HBeAg conversion rate, HBsAg negative conversion rate and HBsAg negative conversion rate. There was no significant difference in HBeAg negative conversion rate and HBV-DNA decrease rate between group B and group C, which were significantly higher than those in group A. The difference was statistically significant (P 0.05), but there was no significant difference between group B and group C in the incidence of adverse reactions. There was no significant difference in the incidence of adverse reactions between group B and group C, and there was no significant difference in the incidence of adverse reactions between group B and group C (P 0.05). Conclusion: Ganoderma lucidum glycopeptide and thymic pentapeptide combined with recombinant human interferon 伪 2b have a good inhibitory effect on chronic hepatitis B virus proliferation, and have the same effect on alt normalization rate and HBeAg conversion rate, decrease of HBsAg and HBsAg negative conversion rate.
【作者单位】：济南市传染病医院七科;山东省医学科学院药物研究所;
【分类号】：R512.62

【参考文献】